AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. This phase 2 study, officially titled “A Phase 2, Open-Label Study to Evaluate the Ef AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. TipRanks Welcomes a...
BackgroundPatients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma who develop resistance to first-generation tyrosine kinase inhibit 2 Materials and methods2.1 Study participants The patient selection process is shown in Figure 1. The initially identified screening cohort consisted of 750...
The epidermal growth factor receptor (EGFR) is frequently dysregulated in certain cancers, including breast cancer. Gefitinib, an EGFR tyrosine kinase inhibitor (TKI) used in non-small cell lung cancer, was proposed for breast cancer treatment. The use of TKI in combination...
AbstractStudy design Retrospective study. Objective To investigate the association between endplate defects and patient-reported outcomes and to further clarify the role of lipotoxicity-induced EGFR/COX-2 signalling in the pathogenesis of low back pain. Summary of background data As the hub of...
BackgroundPatients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) inevitably develop resistance to EGFR-tyrosine kina Abstract Background: Patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) inevitably develop resistance to EGFR-tyrosine kinase inhibitors (TKIs)....
AbstractMultiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that results from oligodendrocyte loss and multifocal demyelination of the CNS white matter. Current therapies can suppress the progression of CNS inflammation but do not actively promote...
Abstract EGFR is a validated therapeutic target for non-small cell lung cancer (NSCLC). Herein, we designed and synthesized a series of gefitinib-based hydrophobic tagging (Hyt) degraders to induce EGFR degradation. Among them, B3 was identified as an active degrader, with...
AbstractBackground EGFR-mutant lung adenocarcinoma (LUAD) exhibits significant prognostic heterogeneity despite the efficacy of tyrosine kinase inhibitors. To uncover the transcriptomic markers of rapid disease progression, we integrated clinical and transcriptomic data to develop robust prognostic biomarkers for risk stratification. Methods...
Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) remains a major challenge in the treatment of non-small cell lung cancer (NSCLC). To address this issue, we developed a novel therapeutic strategy based on multiparatopic antibodies that...
Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb Co. (BMY) is launching a Phase III lung cancer trial c Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. TipRanks Welcomes a...
